Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Acerta Pharma BV
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Roswell Park Cancer Institute
Columbia University
Mayo Clinic
Fred Hutchinson Cancer Center
Mirror Biologics, Inc.
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Ciusss de L'Est de l'Île de Montréal
University of Michigan Rogel Cancer Center
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Singapore General Hospital
National Cancer Institute (NCI)
Polyphor Ltd.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Erlangen-Nürnberg Medical School
University of Kentucky
National Cancer Institute (NCI)
Asan Medical Center
M.D. Anderson Cancer Center
Washington University School of Medicine
Baylor College of Medicine
Northwestern University
UNC Lineberger Comprehensive Cancer Center
Accenture
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center